Hepatitis B virus infection in a cohort of HIV infected blood donors and AIDS patients in Sichuan, China

Journal of Translational Medicine

Zhong Liu²  Miao He¹  Ling Ke²  Min Xu¹  Gui Liu²  Jingxing Wang¹  Peibin Zeng¹  Yu Liu² 

[1] Department of infectious disease, Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Hua Cai Road 26 Hao, Dong San Huan Road Er Duan, Chengdu, Sichuan, China;Experimental center of transfusion medicine, Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Hua Cai Road 26 Hao, Dong San Huan Road Er Duan, Chengdu, Sichuan, China

关键词: AIDS patients;    Blood donors;    HBV;    HIV;   

Others  :  810485
DOI  :  10.1186/1479-5876-12-164

 received in 2014-03-15, accepted in 2014-05-09,  发布年份 2014

【 摘 要 】

Background

Co-infections of HBV and HIV are frequent due to similar routes of transmission. In that transmission through blood is an important route for both HBV and HIV, evaluation of the prevalence of HBV in HIV infected blood donors may be important for transfusion safety. In addition, because the epidemiological characteristics of HBV in HIV infected patients and blood donors may differ from each other, understanding of it could be significant for therapy and prevention of HBV in HIV infected adults. However, data reported on these in Chinese people remains limited.

Methods

614 HIV confirmed positive samples were collected from blood donors and patients and were screened for HBsAg and HBV DNA. The samples screened reactive for HBsAg or positive for HBV DNA were tested for the other serological markers of HBV including anti-HBs, HBeAg, anti-HBe and anti-HBc. For the samples tested positive for HBV DNA, the S region of HBV was amplified by nested PCR and the HBV genotypes were determined.

Results

HBV coinfections were found in 12.9% (79/614) HIV infected individuals including 42/417(10.1%) blood donors and 37/197 (18.8%) AIDS patients. In the HBsAg positive individuals, 80.0% were HBeAg negative in which 10.0% were HBV DNA negative and 38.3% with HBV DNA lower than 2000 IU/ml. The average HBV DNA levels were lower in donors than in patients. In the HBV DNA positive populations, HBV genotypes B, A and C accounted for 48.1%, 22.8% and 8.86% respectively. Mutations related to the failure of HBsAg detection were found in 2 of the 4 HBsAg-/HBV DNA + subjects.

Conclusions

High prevalence of HBV in HIV infected individuals was found in this study. Hence, we recommend routine testing of HBV for patients newly diagnosed with HIV/AIDS in China. Some HIV-HBV co-infected patients remain undiagnosed if only conventional serological markers for HBV are used and it’s important to detect HBV DNA for HIV infected patients. HBV DNA levels were relatively low in HBeAg negative patients, thus this serologic marker may be useful in prioritizing patients on their need for HBV treatment in settings in which HBV DNA is not available.

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Koziel MJ, Peters MG: Viral hepatitis in HIV infection. N Engl J Med 2007, 356(14):1445-1454.
• [2]Puoti M, Torti C, Bruno R, Filice G, Carosi G: Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006, 44(1 Suppl):S65-S70.
• [3]Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360(9349):1921-1926.
• [4]Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J: Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008, 22(12):1399-1410.
• [5]Thio CL: Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003, 23(2):125-136.
• [6]Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Wang Y, Bi S: General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS ONE 2009, 4(12):e8467.
• [7]Yan YX, Gao YQ, Sun X, Wang W, Huang XJ, Zhang T, Li M, Zang CP, Li ZC, Wu H: Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. Epidemiol Infect 2011, 139(3):354-360.
• [8]Zhao YS, Su SI, Lv CX, Zhang XF, Lin L, Sun XG, Lin B, Fu JH: Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China. Int J STD AIDS 2012, 23(9):639-643.
• [9]Kramvis A, Kew M, Francois G: Hepatitis B virus genotypes. Vaccine 2005, 23(19):2409-2423.
• [10]Yin J, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, Cui F, Liang X, Schaefer S, Cao G: Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 2010, 19(3):777-786.
• [11]Liu Y, Wang J, Huang Y, Yang T, Guo X, Li J, Wen G, Yun Z, Zeng P, He M, Xu M, Liu G, Ke L, Wright D, Liu J, Nelson K, Shan H: Molecular epidemiological study of hepatitis B virus in blood donors from five Chinese blood centers. Arch Virol 2012, 157(9):1699-1707.
• [12]Li D, Gu HX, Zhang SY, Zhong ZH, Zhuang M, Hattori T: YMDD mutations and genotypes of hepatitis B virus in northern China. Jpn J Infect Dis 2006, 59(1):42-45.
• [13]Avellon A, Echevarria JM: Frequency of hepatitis B virus ‘a’ determinant variants in unselected Spanish chronic carriers. J Med Virol 2006, 78(1):24-36.
• [14]Thomas DL: Growing importance of liver disease in HIV-infected persons. Hepatology 2006, 43(2 Suppl 1):S221-S229.
• [15]Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48(2):353-367.
• [16]Thio CL, Smeaton L, Saulynas M, Hwang H, Saravan S, Kulkarni S, Hakim J, Nyirenda M, Iqbal HS, Lalloo UG, Mehta AS, Hollabaugh K, Campbell TB, Lockman S, Currier JS: Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 2013, 27(2):191-201.
• [17]Gupta S, Singh S: Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis 2010, 10:53. BioMed Central Full Text
• [18]Echevarria JM, Avellon A: Improved detection of natural hepatitis B virus surface antigen (HBsAg) mutants by a new version of the VITROS HBsAg assay. J Med Virol 2008, 80(4):598-602.
• [19]Avellon A, Echevarria JM, Weber B, Weik M, Schobel U, Willems WR, Gerlich WH: European collaborative evaluation of the Enzygnost HBsAg 6.0 assay: performance on hepatitis B virus surface antigen variants. J Med Virol 2011, 83(1):95-100.
• [20]Reuter S, Oette M, Wilhelm FC, Beggel B, Kaiser R, Balduin M, Schweitzer F, Verheyen J, Adams O, Lengauer T, Fätkenheuer G, Pfister H, Häussinger D: Prevalence and characteristics of hepatitis B and C virus infections in treatment-naive HIV-infected patients. Med Microbiol Immunol 2011, 200(1):39-49.
• [21]Grumayer ER, Panzer S, Ferenci P, Gadner H: Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. J Hepatol 1989, 8(2):232-235.
• [22]Waite J, Gilson RJ, Weller IV, Lacey CJ, Hambling MH, Hawkins A, Briggs M, Tedder RS: Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 1988, 2(6):443-448.